In radiopharmaceutical therapy (RPT), a radionuclide is systemically or locally delivered with
the goal of targeting and delivering radiation to cancer cells while minimizing radiation …

The underlying principles of nuclear medicine imaging involve the use of unsealed sources
of radioactivity in the form of radiopharmaceuticals. The ionizing radiations that accompany …

89Zr (half-life, 78.41 h) is a positron-emitting radionuclide that displays excellent potential for
use in the design and synthesis of radioimmunoconjugates for immunoPET. In the current …

Zirconium-89 is an attractive metallo-radionuclide for use in immuno-PET due to favorable
decay characteristics. Standardized methods for the routine production and isolation of high …

The development of novel multimodality imaging agents and techniques represents the
current frontier of research in the field of medical imaging science. However, the …

Purpose Besides PSMA, prostate cancer cells also express gastrin-releasing peptide
receptor (GRPr) which is therefore a promising target for theranostic approaches. The high …

A modular system for the construction of radiometalated antibodies was developed based
on the bioorthogonal cycloaddition reaction between 3-(4-benzylamino)-1, 2, 4, 5-tetrazine …

A novel reaction for chelate-free, heat-induced metal ion binding and radiolabeling of ultra-
small paramagnetic iron oxide nanoparticles (USPIOs) has been established …

On behalf of the EANM Physics Committee: Ellinor Busemann Sokole & Anna Płachcínska &
Alan Britten With contribution from the EANM Working Group on Nuclear Medicine …

Background The positron-emitting radionuclide 89Zr (t 1/2= 3.17 days) was used to prepare
89Zr-radiolabeled trastuzumab for use as a radiotracer for characterizing HER2/neu-positive …